fadrozole has been researched along with Menopause in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 9 (81.82) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Inoue, M; Kasai, T; Murakami, K; Segawa, T; Shozu, M | 1 |
| Hasegawa, Y; Nakao, K; Tanaka, M; Yano, S | 1 |
| Abe, O; Ando, J; Enomoto, K; Fujiwara, K; Hayashi, K; Hisamatsu, K; Imoto, S; Nomura, Y; Tashiro, H; Tominaga, T | 1 |
| Bonomi, P; Buzdar, AU; Cooper, J; Favis, G; Keller, AM; Mulagha, M; Smith, R; Vogel, C | 1 |
| Falkson, G; Falkson, HC; Raats, JI | 1 |
| Demers, LM; Garber, JE; Hanagan, J; Harvey, H; Henderson, IC; Lipton, A; Lynch, J; Mulagha, M; Navari, RM; Santen, RJ | 1 |
| Coombes, RC; Davenport, J; Dowsett, M; Ford, HT; Gazet, JC; Hedley, A; Stein, RC | 1 |
| Demers, LM; Fitzsimmons, S; Hanagan, JR; Harvey, HA; Kochak, GM; Lipton, A; Mulagha, MT; Sanders, SI; Santen, RJ | 1 |
| Dowsett, M; Lønning, PE; Powles, TJ | 1 |
| Coombes, RC; Dowsett, M; Mehta, A; Stein, RC | 1 |
| Adlercreutz, H; Demers, LM; Harvey, H; Lipton, A; Sanders, S; Santen, RJ; Santner, S | 1 |
1 review(s) available for fadrozole and Menopause
| Article | Year |
|---|---|
Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer.
Topics: Aminoglutethimide; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Estrogens; Fadrozole; Female; Humans; Imidazoles; Menopause; Nitriles | 1990 |
4 trial(s) available for fadrozole and Menopause
| Article | Year |
|---|---|
[Phase I study of CGS16949A--a new aromatase inhibitor. Cooperative Study Group for CGS16949A].
Topics: Administration, Oral; Adult; Aged; Androgens; Breast Neoplasms; Drug Administration Schedule; Estrogens; Fadrozole; Female; Humans; Menopause; Middle Aged; Neoplasms, Hormone-Dependent | 1994 |
Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma; Double-Blind Method; Fadrozole; Female; Humans; Megestrol; Menopause; Middle Aged; Prognosis; Prospective Studies; Survival Analysis | 1996 |
A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Evaluation; Estrogen Antagonists; Fadrozole; Female; Humans; Imidazoles; Life Tables; Menopause; Middle Aged; Nitriles; Survival Analysis; Treatment Outcome | 1992 |
Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogens; Estrone; Fadrozole; Female; Gonadal Steroid Hormones; Humans; Imidazoles; Menopause; Middle Aged; Neoplasm Metastasis; Nitriles; Randomized Controlled Trials as Topic | 1990 |
6 other study(ies) available for fadrozole and Menopause
| Article | Year |
|---|---|
Successful treatment of a symptomatic uterine leiomyoma in a perimenopausal woman with a nonsteroidal aromatase inhibitor.
Topics: Aromatase Inhibitors; Enzyme Inhibitors; Estradiol; Fadrozole; Female; Follicle Stimulating Hormone; Humans; Leiomyoma; Luteinizing Hormone; Menopause; Middle Aged; Uterine Neoplasms | 2003 |
Antiproliferative effect of the new aromatase inhibitor fadrozole on pre- and postmenopausal models of rat mammary tumor.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Androstenedione; Animals; Antineoplastic Agents; Aromatase Inhibitors; Fadrozole; Female; Hormones; Mammary Neoplasms, Experimental; Menopause; Ovariectomy; Rats; Rats, Sprague-Dawley | 1994 |
Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor.
Topics: 17-alpha-Hydroxyprogesterone; Adrenocorticotropic Hormone; Aldosterone; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrone; Fadrozole; Female; Humans; Hydrocortisone; Hydroxyprogesterones; Imidazoles; Kinetics; Menopause; Nitriles | 1991 |
Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A.
Topics: Aldosterone; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Evaluation; Electrolytes; Estradiol; Fadrozole; Female; Humans; Imidazoles; Menopause; Nitriles; Receptors, Estrogen | 1990 |
A phase I trial of CGS 16949A. A new aromatase inhibitor.
Topics: Adult; Aged; Androgens; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Drug Evaluation; Estrogens; Fadrozole; Female; Humans; Imidazoles; Lymphatic Metastasis; Menopause; Middle Aged; Nitriles | 1990 |
Inhibition of aromatase with CGS 16949A in postmenopausal women.
Topics: Administration, Oral; Aged; Aged, 80 and over; Androgens; Aromatase Inhibitors; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Tolerance; Estrogens; Fadrozole; Female; Humans; Hydrocortisone; Imidazoles; Menopause; Nitriles | 1989 |